THE FUTURE OF IMMUNOTHERAPY: CAR-T AN INNOVATIVE THERAPY IN ONCO-HEMATOLOGY AND ITS LIMITATIONS FOR SOLID TUMORS
DOI:
https://doi.org/10.47820/recima21.v4i1.3329Keywords:
increasing development of the use of immunotherapyAbstract
With the increasing development of the use of immunotherapy of oncological diseases, the treatment with CAR-T cells (T lymphocytes with Chimeric Antigen Receptors), strategies are being used to take advantage of the immune system itself to fight cancers. The innovative technique of cell therapy, has been obtaining impressive results in cases that no longer had therapeutic options left whose prognoses were weak and practically unlikely, studies presented expose both limitations for solid tumors and side effects from the release of cytokines, as advances in the reprogramming of T lymphocytes in their production, benefiting hematological patients. Advances have been presented in the creations of the generations of CAR-T cells, we know that there are four generations, based on the development of the first generation. They showed limited efficacy in terms of persisting the antitumor response. It is important to note that these generations represent major advances in the reformulation of CAR-T cells and in intracellular activation and signaling strategies, with the aim of improving therapeutic efficacy. The present study is justified by the interest in exposing data and details of CAR-T cell therapy, which represents an advance in science and in the treatment of patients suffering from hematological neoplasms. Concept, technology and process for advanced therapies are presented, where the clinical application is addressed, being presented products already approved as: Kymriah, Yescarta.
Downloads
References
NATIONAL INSTITUTES OF HEALTH. CAR T Cells: Engineering Patient’s Immune Cells to Treat Their Cancers. 2017. [citado em 21 de fevereiro de 2023]. Disponível em:<https://www.cancer.gov/about-cancer/treatment/research/car-t-cells>
A história da terapia CAR-T: 60 anos de evolução e pioneirismo em direção à cura docâncer – Hemocentro RP [Internet]. [citado em 11 de março de 2023]. Disponível em: https://www.hemocentro.fmrp.usp.br/a-historia-da-terapia-car-t-60-anos-de-evolucao- e-pioneirismo-em-direcao-a- curadocancer/#:~:text=1987%3A%20Criado%20o%20primeiro%20receptor
Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018 Jul;8(4):539-551.
Ti D, Niu Y, Wu Z, Fu X, Han W. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy. Sci China Life Sci. 2018;61(11):1320–32.
Pule M, Finney HLA. 2003. Artificial T-cell receptors. Cytotherapy 5(3):211-226.
Abbas AK; Lichtman AH; Pillai SHIV. Imunologia celular e molecular. 7. Ed. Rio de Janeiro: Elsevier, 2012. 90-93p
Mesquita JD, Araújo JAP, Catelan TTT, Souza AWS, Crunivel WM, Andrade LEC, et al. Sistema imunitário – parte II: fundamentos da resposta imunológica mediada por linfócitos T e B. Revista Brasileira de Reumatologia. 2010 oct;50(5):552-80
Sun ZJ, Kim KS, Wagner G, Reinher EL. Mechanism contributing to T cell receptor signaling and assembly revealed by the solution structure of an ectodomain of the CD3 heterodimer. Cell. 2001; 105:913-23.
Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, and Darcy PK. 2002. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood
(9):3155-3163.
Guedan S, Chen X, Madar A, Carpenito C, mcgettigan SE, Frigault MJ, et al. ICOS- based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood. 2014 Aug 14;124(7):1070-80.
Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology. 2012 Jul 1;1(4):458-466.
Mata M, Gerken C, Nguyen P, Krenciute G, Spencer DM, Gottschalk S. Inducible Activation of myd88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models. Cancer Discov. 2017 Nov;7(11):1306-1319.
Song DG; Powell DJ. Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapyoncoimmunology, 2012
Santis GC, Junior DML, Feitosa A, Junior AM, Kutner JM, Covas DT etal. Consenso da Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular sobre Células Geneticamente Modificadas.V: Manufatura e Controle de Qualidade.2021. [citado em 1 de março de 2023]. Disponível em: https://doi.org/10.1016/j.htct.2021.09.005
Rohit Reddy S, Llukmani A, Hashim A, Haddad DR, Patel DS, Ahmad F, Abu Sneineh M, Gordon DK. The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead. Cureus. 2021 Feb 25;13(2): e13552
Li Y, Ming Y, Fu R, Li C, Wu Y, Jiang T, Li Z, Ni R, Li L, Su H, Liu Y. The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front Pharmacol. 2022 Oct 14; 13:950923.
Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front Immunol. 2022 Jun 10; 13:927153.
Silva EV de S, Nascente E de P, Miguel MP, Alves CEF, Moura VMBD de. Elucidating tumor immunosurveillance and immunoediting: a comprehensive review. Ciênc anim bras [Internet]. 2021[citado em 12 de janeiro de 2023] ;22(Ciênc. Anim. Bras., 2021 22). Disponível em: https://doi.org/10.1590/1809-6891v22e-68544
Martinez M, Moon EK. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol. 2019 [citado em
de fevereiro de 2023] Feb 5; 10:128. Disponivel em https://doi.org/10.3389/fimmu.2019.00128. PMID: 30804938; PMCID: PMC6370640.
Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z, Qian Q. Current Progress in CAR-T Cell Therapy for Solid Tumors. Int J Biol Sci. 2019 Sep [citado em 24 de fevereiro de 2023] 7;15(12):2548-2560.Disponivel em https://doi.org/ 10.7150/ijbs.34213. PMID: 31754328; PMCID: PMC6854376.
GOLDSBY, R. A; KINDT, T. J; OSBORNE, B. A. Kuby Imunologia. Tradução Solange Cristina Davino. 4. Ed. Rio de Janeiro: Revinter, 2002. 662p
Chung H, Jung H, Noh JY. Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy. Int J Mol Sci. 2021 Nov 9[citado em 28 de fevereiro];22(22):12126. Disponivel em https://doi.org/10.3390/ijms222212126. PMID: 34830003; PMCID: PMC8621681.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
Clique para ver detalhes 
